Starpharma Holdings Limited: Q1 Cash Flow Report

Starpharma Holdings Limited (ASX: SPL) During the first quarter of fiscal year 2024, the compantachieved significant milestones. The company received AU$6.6 million from Mundipharma as part of the VivaGel® BV settlement agreement. Noteworthy clinical trial results were reported: the DEP® cabazitaxel Phase 2 trial demonstrated positive responses in various cancers, with a favourable safety profile. Additionally, the DEP® irinotecan interim results showed promising anti-tumor effects in colorectal and ovarian cancers.

Positive data presentations were made for DEP® HER2-zirconium and the DEP® radiotheranostic pipeline at international conferences. Recruitment for all three Phase 2 clinical programs was completed. The VIRALEZE™ antiviral nasal spray study in COVID-19-positive patients finished recruitment. Starpharma closed the quarter with AU$35.6 million in cash, with a net cash inflow of AU$0.4 million. The company received an AU$7.2 million R&D Tax Incentive refund post-quarter end, fortifying its cash position.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com